Nxera Pharma Co., Ltd. (TYO:4565)
Japan
· Delayed Price · Currency is JPY | Market Cap | 79.38B |
| Revenue (ttm) | 28.84B |
| Net Income (ttm) | -4.84B |
| Shares Out | 89.90M |
| EPS (ttm) | -53.92 |
| PE Ratio | n/a |
| Forward PE | 75.82 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,200 |
| Average Volume | 1,255,840 |
| Open | 892.00 |
| Previous Close | 885.00 |
| Day's Range | 876.00 - 894.00 |
| 52-Week Range | 668.00 - 1,754.00 |
| Beta | 0.38 |
| RSI | 55.94 |
| Earnings Date | May 2, 2025 |
About Nxera Pharma
Nxera Pharma Co., Ltd. develops and sells pharmaceutical products in Japan, the United States, Germany, Switzerland, Bermuda, and the United Kingdom. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist i... [Read more]
Financial Performance
In 2024, Nxera Pharma's revenue was 28.84 billion, an increase of 125.87% compared to the previous year's 12.77 billion. Losses were -4.84 billion, -32.74% less than in 2023.
Financial StatementsNews
Nxera Pharma Announces Appointments to its Executive Leadership Team
Tokyo, Japan and Cambridge, UK, 1 April 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces two new appointments to its Leadership team: Mr. Kiyoshi Kaneko, is appointed...
Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a pot...
Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan
Tokyo, Japan and Cambridge, UK, 28 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has entered a license, supply and commercialization agreement with Holl...
Nxera Pharma Proposes Changes to its Board of Directors
Tokyo, Japan and Cambridge, UK, 14 February 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated b...
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024
Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the...
Nxera Pharma Webinar Presentation for FY2024 Financial Results
Tokyo , Japan and Cambridge, UK, 23 January 2025 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the year ended 31 December 2024 on...
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio
Tokyo, Japan and Cambridge, UK, 14 January 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) is pleased to report on progress being made by Neurocrine Biosciences, Inc. (“Neurocrine”)...
Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill, Preside...
Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia
Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Shionogi & Co., Ltd. (“Shionogi”)...
Nxera Pharma Enrolls First Insomnia Patient in its Phase 3 Clinical Trial of Daridorexant in South Korea
Tokyo, Japan and Cambridge, UK, 5 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces randomization of the f...
Nxera Pharma's Partner Centessa Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 13 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes that Centessa Pharmaceuticals h...
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies fo...
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational acti...
Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024
Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won...
Nxera Pharma to Host R&D Day 2024
Nxera Pharma Co., Ltd. will hold an R&D Day on 6 November 2024 at 16:30 JST. The meeting will be held virtually via Zoom webinar. Please click here to pre-register for the event.
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Dr. ...
Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan
Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co., ...
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
Tokyo, Japan and Cambridge, UK, 24 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Nxera Pharma Japan Co...
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Tokyo, Japan and Cambridge, UK, 11 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by Centessa P...
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$3...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2024
Tokyo, Japan and Cambridge, UK, 9 August 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quar...
Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results
Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June 2024 on Frid...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
Tokyo, Japan and Cambridge, UK, 27 June 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone under its multi-target discovery collaboration with Ab...
Nxera Pharma Publishes its Annual and ESG Reports for the Year ended 31 December 2023
Tokyo, Japan and Cambridge, UK, 18 June 2024 – Nxera Pharma (“Nxera” or “the Company”; TSE 4565), today announces the publication of its Annual Report and its Environment, Social & Governance (ESG) Re...
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa Pharmaceuti...